Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza vaccine (split virion), inactivated, quadrivalent, ZFA02-adjuvanted
- Development stage
- Approved
- Lead developer
- Anhui Zhifei Longcom Biopharmaceutical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a quadrivalent, inactivated, split-virion influenza vaccine developed by Anhui Zhifei Longcom Biopharmaceutical. It is formulated with the proprietary ZFA02 adjuvant to enhance immunogenicity. The vaccine targets four strains of the influenza virus: two influenza A subtypes (H1N1 and H3N2) and two influenza B lineages (Victoria and Yamagata). By using a split-virion approach, the virus is chemically disrupted to reduce reactogenicity while maintaining the presence of key surface antigens like hemagglutinin and neuraminidase. The addition of the ZFA02 adjuvant is intended to provoke a more robust and long-lasting immune response, which is particularly beneficial for populations with waning immunity, such as the elderly.
- Other names
- Adjuvanted Quadrivalent Influenza Vaccine (Split Virion), Inactivated
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on influenza vaccine (split virion), inactivated, quadrivalent, ZFA02-adjuvanted.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza vaccine (split virion), inactivated, quadrivalent, ZFA02-adjuvanted.